Allarity Therapeutics (Allarity Therapeutics) EBIT per Share : $-169.09 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics EBIT per Share?

Allarity Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-10.92. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-169.09.

During the past 3 years, the average EBIT per Share Growth Rate was 50.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Allarity Therapeutics's EBIT per Share or its related term are showing as below:

ALLR' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 20.6 Med: 35.4 Max: 50.2
Current: 50.2

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Allarity Therapeutics was 50.20% per year. The lowest was 20.60% per year. And the median was 35.40% per year.

ALLR's 3-Year EBIT Growth Rate is ranked better than
93.64% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs ALLR: 50.20

Allarity Therapeutics's EBIT for the three months ended in Mar. 2024 was $-3.75 Mil.

Allarity Therapeutics EBIT per Share Historical Data

The historical data trend for Allarity Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics EBIT per Share Chart

Allarity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-2,610.83

-1,016.50

-3,234.38

-867.80

-113.20

Allarity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial											-3,260.00	-117.79	-35.59	-4.79	-10.92

Allarity Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Allarity Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.32	/	0.100
=	-113.20

Allarity Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.745	/	0.343
=	-10.92

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-169.09

Allarity Therapeutics (NAS:ALLR) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Allarity Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Allarity Therapeutics (Allarity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

24 School Street, 2nd Floor, Boston, MA, USA

Website

https://www.allarity.com

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Executives

Laura Benjamin	director	168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano	director	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin	director	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown	officer: Chief Financial Officer	C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi	director, officer: Chief Executive Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen	officer: Chief Scientific Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen	officer: Chief Financial Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen	director	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore	director	C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen	officer: SVP, Information Technology	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem	officer: SVP, Chief Business Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh	officer: Chief Medical Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps	10 percent owner	VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass	10 percent owner	JERNBAEK ALLE 5, HELSINGE G7 DK-3200